Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 40039, held by Taro. Triamcinolone Acetonide.
As of Nov 15, 2026, ANDA 40039 (Triamcinolone Acetonide), held by Taro, was first approved by FDA on Nov 26, 1997, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Triamcinolone acetonide cream, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 26, 1997 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Triamcinolone Acetonide0.1% · cream;topical | Triamcinolone Acetonide | Rx |
| Nov 27, 2019 | Supplement 17Labeling · Standard review | Approved | None posted |
| Jun 15, 2005 | Supplement 3Labeling | Approved | None posted |
| Nov 26, 1997 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
